Eton's quarterly revenue more than doubles as it lifts 2026 targets
Product sales reached $57.9m in the third quarter, and the company now expects full-year revenue above $175m with an adjusted EBITDA margin of at least 40%.
Eton Pharmaceuticals reported third-quarter 2026 product sales of $57.9m on 5 November, against $22.5m in the same quarter a year earlier. That is growth of 158%, or about $35m in additional quarterly revenue. The material available does not say which products drove the increase.
Alongside the results, the company raised its full-year 2026 guidance. It now expects revenue above $175m and an adjusted EBITDA margin of at least 40%. The earlier guidance figures were not included in the information provided, so the size of the increase cannot be stated.
Eton also pointed to two US regulatory milestones in 2027. The FDA has set a goal date of 29 March 2027 for the new drug application covering LIBERVANT in children aged 6 to 11, a product Eton has newly licensed. A goal date of 28 May 2027 applies to the proposed label expansion for KHINDIVI. These dates are when the agency aims to finish its review; they do not guarantee an outcome.
The company said it had made progress on ASN-001, ET-900, ET-700, harmonisation of the INCRELEX label and Glyburide Oral Suspension. No further detail on the stage or timing of those programmes was available.
Why it matters
- A 158% year-on-year rise in quarterly sales, together with guidance above $175m, shows a sharp step-up in scale for a small specialty pharma.
- Two FDA decisions, on LIBERVANT (29 March 2027) and KHINDIVI (28 May 2027), fall in the first half of 2027 and could widen the commercial portfolio if they go Eton's way.
- The pipeline update lacked detail on the named programmes, so their commercial contribution cannot yet be assessed.
Company's press release (SEC filing): Eton Pharmaceuticals, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
